This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.
light from the FDA and EMA last year for its Yescarta (axicabtagene ciloleucel) therapy for adults with various types of B-cell lymphoma, including relapsed or refractory DLBCL.
Interest in CAR-T therapies in particular has been growing since the first two products in the category - Novartis’Kymriah (tisagenleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) - were approved for
CAR-T is still considered to be in its infancy with Kite bringing the second therapy to market - Yescarta (axicabtagene ciloleucel) for relapsed or refractory B-cell lymphoma - shortly after
One-year results from the ZUMA-1 trial of Gilead’s Yescarta (axicabtagene ciloleucel) in aggressive non-Hodgkin’s lymphoma, plus six-month data from the JULIET trial of Novartis’Kymriah
CAR-T Yescarta (axicabtagene ciloleucel) in relapsed/refractory B cell lymphoma.
its Yescarta (axicabtagene ciloleucel) in relapsed/refractory B cell lymphoma earlier last week.
More from news
Approximately 1 fully matching, plus 16 partially matching documents found.
Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
At Pegasus, we specialise in helping deliver healthy messages through integrated communication programmes. In fact, inspiring healthy decisions is all...